Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Etonogestrel (ENG), Etonogestrel
etonogestrel with testosterone undecanoate · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | ACTIVE_COMPARATOR | etonogestrel with testosterone undecanoate |
| Arm 2 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| etonogestrel with testosterone undecanoate | DRUG | 42 or 44 weeks with etonogestrel implant and testosterone undecanoate injections every 10 to 12 weeks |
| Placebo | DRUG | 42 or 44 weeks with placebo implant and placebo injections |
Inclusion Criteria: * Male * Mentally and physically healthy * BMI between 18 and 32 kg/m\^2 * Two pre-treatment semen samples \> 20 million/ml with normal morphology and motility Exclusion Criteria: * History or presence of psychiatric disease, liver disease, renal disease, diabetes, cardiovascu...
Etonogestrel with testosterone undecanoate is an investigational small molecule combination being studied for contraception in healthy young men. It pairs etonogestrel, a progestin, with testosterone undecanoate. Organon & Co. (ticker: OGN) is developing it, and it has completed a Phase 2 trial.
Etonogestrel with testosterone undecanoate is being developed for contraception. The completed Phase 2 trial enrolled healthy young men aged 18 years and older. It is not approved for any use and remains an investigational product.
Etonogestrel with testosterone undecanoate targets the progesterone receptor (PGR) as an agonist. Etonogestrel acts as a progestin agonist at PGR, while testosterone undecanoate provides androgen. This combination is being studied for male contraception.
Organon & Co. (ticker: OGN) is developing etonogestrel with testosterone undecanoate. The company is responsible for the clinical program, including the completed Phase 2 trial in healthy young men for contraception.
Etonogestrel with testosterone undecanoate is in Phase 2 development. One Phase 2 trial has been completed, and no active trials are ongoing. It is investigational and has not been approved by the FDA.
Etonogestrel with testosterone undecanoate has been studied in one completed Phase 2 trial, NCT00403793, titled Hormonal Contraception in Healthy Young Men. The trial enrolled 350 participants, was randomized, double-blind, and placebo-controlled, and included healthy male volunteers aged 18 years and older.
Etonogestrel with testosterone undecanoate is a combination product that includes etonogestrel, also known as ENG. Etonogestrel alone is a progestin used in other contraceptives, but this specific combination with testosterone undecanoate is a distinct investigational product developed by Organon.